Harnessing native-cryptic plasmids for stable overexpression of heterologous genes in Clostridium butyricum DSM 10702 for industrial and medical applications.

Clostridium butyricum has emerged as a promising candidate for both industrial and medical biotechnologies, underscoring the key pursuit of stable gene overexpression in engineering C. butyricum. Unlike antibiotic-selective vectors, native-cryptic plasmids can be utilized for antibiotic-free expression systems in bacteria but have not been effectively exploited in C. butyricum to date. This study focuses on leveraging these plasmids, pCB101 and pCB102, in C. butyricum DSM10702 for stable gene overexpression without antibiotic selection via efficient gene integration using the SacB-based allelic exchange method. Integration of reporter IFP2.0 and glucuronidase generated sustained near-infrared fluorescence and robust enzyme activity across successive subcultures. Furthermore, successful secretion of a cellulase, Cel9M, and the human interleukin 10 from pCB102 highlights native-cryptic plasmids' potential in conferring stable gene products for industrial and medical applications in C. butyricum. This work appears to be the first study to harness the Clostridium native-cryptic plasmid for stable gene overexpression without antibiotics, thereby advancing the biotechnological prospects of C. butyricum.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests. Philippe Lambin reports a relationship with Radiomics SA that includes: equity or stocks and funding grants. Philippe Lambin reports a relationship with Convert Pharmaceuticals SA that includes: equity or stocks and funding grants. Philippe Lambin reports a relationship with LivingMed Biotech srl that includes: equity or stocks and funding grants. Philippe Lambin reports a relationship with BHV srl that includes: consulting or advisory and travel reimbursement. Philippe Lambin reports a relationship with Roche that includes: consulting or advisory and travel reimbursement. Philippe Lambin reports a relationship with Comunicare SA that includes: equity or stocks. Philippe Lambin reports a relationship with Bactam srl that includes: equity or stocks. Ludwig J. Dubois reports a relationship with Convert Pharmaceuticals SA that includes: equity or stocks. Ludwig J. Dubois reports a relationship with LivingMed Biotech srl that includes: equity or stocks. Jan Theys reports a relationship with Convert Pharmaceuticals SA that includes: equity or stocks. Yanchao Zhang has patent pending to Maastricht University. Jan Theys has patent pending to Maastricht University. Philippe Lambin has patent pending to Maastricht University. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Authors. Published by Elsevier GmbH.. All rights reserved.)